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Background: Because of the described hazards related to inhalation of manufactured 
  nanoparticles, we investigated the lung toxicity of biodegradable poly (lactide-co-glycolide) 
(PLGA) nanoparticles displaying various surface properties on human bronchial Calu-3 cells.
Methods: Positively and negatively charged as well as neutral nanoparticles were tailored by 
coating their surface with chitosan, Poloxamer, or poly (vinyl alcohol), respectively. Nanoparticles 
were characterized in terms of size, zeta potential, and surface chemical composition, confirming 
modifications provided by hydrophilic polymers.
Results: Although nanoparticle internalization by lung cells was clearly demonstrated, the 
cytotoxicity of the nanoparticles was very limited, with an absence of inflammatory response, 
regardless of the surface properties of the PLGA nanoparticles.
Conclusion: These in vitro results highlight the safety of biodegradable PLGA nanoparticles in 
the bronchial epithelium and provide initial data on their potential effects and the risks associ-
ated with their use as nanomedicines.
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Introduction
Most of the studies that have investigated the toxic effects of nanoparticles on the 
lungs have focused on inorganic nanoparticles, such as carbon nanotubes, fullerenes, 
and silica and metal nanoparticles, as well as urban particulate matter.1–3 The harm-
ful effects observed for these nanoparticles were correlated with common biological 
mechanisms, eg, inflammation and oxidative stress. Indeed, both carbon nanotubes and 
urban particulate matter are responsible for the activation of proinflammatory pathways 
in macrophages, with robust acute inflammatory responses leading to a rapid onset of 
chronic lung fibrosis, extensive granulomas, and other pathologies.3–6 Moreover, these 
systems, as well as metal and silica nanoparticles, induce oxidative stress associated 
with an increase in reactive oxygen species production and the expression of antioxi-
dant enzymes.7,8 It has been further shown that the toxicological profile and biological 
response to the different nanoparticles are closely correlated with their physicochemi-
cal properties because, for instance, amorphous silica nanoparticles have a different 
toxicity profile compared with the crystalline ones.9 Finally, it has been reported that 
simple addition of a thin silica layer on different stable, inert, and nontoxic crystalline 
polymorphs of titanium oxide leads to an increase in cytotoxicity.10
Although these results have raised suspicions about the potential lung toxicity of 
nanoparticles, various nanoscale systems made of biodegradable polymers or lipids 
have been applied to the formulation of nanomedicines designed for the pulmonary International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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route of administration. Lung delivery of nanomedicines 
represents a suitable alternative to parenteral administra-
tion since it allows the administration of fragile and poorly 
absorbed molecules.11–14 Nanoparticles are highly bioavail-
able after lung administration since they are well retained 
in situ and only weakly taken up by alveolar macrophages, 
providing their diameter is around 250 nm.15 Recent studies 
have demonstrated the impressive potential of biodegradable 
nanoparticles for lung delivery of salbutamol.16 However, in 
contrast with inorganic nanoparticles, the lung toxicity of 
biodegradable nanoparticles has not been extensively investi-
gated in the literature. Most studies have assumed that due to 
their biodegradability, these nanoparticles do not lead to side 
effects or toxicity. However, previous results from our group 
contrast with this general view. Indeed, despite their biode-
gradability, specific risks might arise from the nanoparticle 
form itself. It has been demonstrated that, after intravenous 
administration, biodegradable polyalkylcyanoacrylate or 
poly (lactide-co-glycolide) (PLGA) nanoparticles can trigger 
inflammation and, in the case of poly (alkylcyanoacrylate), 
oxidative stress during both acute and chronic treatments.17–19 
However, these effects were reversible after interruption of 
the treatment, which was not the case for non-biodegradable 
polystyrene nanoparticles. Nevertheless, the question about a 
similar deleterious effect on the lung remains open, and the 
goal of the present paper is to answer this question.
Several in vitro models have been developed to study 
the potential toxicity of inhaled materials, and most studies 
have been carried out on the A549 cell line which is repre-
sentative of the alveolar epithelial barrier.20,21 Surprisingly, 
only a small number of studies has been performed on the 
Calu-3 cell line which is representative of the bronchial epi-
thelial barrier. Calu-3 cells derive from a human bronchial 
adenocarcinoma and maintain the properties of the original 
submucosal glands, which are involved in the secretion of 
airway mucus components and mediators of the inflamma-
tory response.22,23 Given that bronchial epithelial cells will 
be the first to be met by inhaled nanoparticles, we considered 
the Calu-3 cell line to be an interesting model to investigate 
the potential toxicity of nanomedicines.
Basic toxicological evaluation of PLGA nanoparticles 
loaded with various drugs has been carried out24,25 and, in a 
recent study, the genotoxicity of such nanoparticles has been 
investigated. In that report, no adverse effect was observed.26 
However, since the genotoxic potential of nanoparticles is 
strongly dependent on their surface properties,27 the role of 
nanoparticle surface chemistry and surface charge on their 
in vitro toxicity needed to be   investigated thoroughly. In the 
present work, we have designed three types of   surface-modified 
nanoparticles, ie, positively and negatively charged as well 
as neutral, and performed a direct comparison of the various 
surface coatings. Among the wide variety of available biode-
gradable polymers, we have chosen to formulate nanoparticles 
with PLGA, which represents one of the most commonly 
used biodegradable and biocompatible polymers involved in 
the formulation of nanomedicines.28,29 Nanoparticle surface 
chemistry and surface charge were then tuned by varying the 
nature of the stabilizer in the formulation. The in vitro cyto-
toxicity, cellular uptake, and inflammatory response induced 
by the different nanoparticles were all assessed using the 
Calu-3-based model of lung epithelium.
Material and methods
chemicals
PLGA (75:25 Resomer® RG756 and 50:50 Resomer RG503H) 
were purchased from Boehringer-Ingelheim (Ingelheim, 
Germany). Polyvinyl alcohol (PVA, 87%–89% hydrolyzed, 
molecular weight 30–70 kDa), and 4-dimethylaminopyridine 
(99%) were obtained from Sigma Aldrich (Lyon, France). 
N,N′-dicyclohexylcarbodiimide (.99%) was purchased from 
Fluka (Paris, France). Rhodamine B alcohol was synthesized 
as described elsewhere.30 Mowiol® 4-88 PVA (molecular 
weight 30 kDa) was a gift from Kuraray Specialities Europe 
GmbH (Frankfurt, Germany). Ultrapure chitosan chloride 
(CS, Protasan® UP CL113, 75%–90% deacetylation, 
molecular weight 50–150 kDa) was purchased from 
NovaMatrix (FMC BioPolymer, Drammen, Norway). 
Poloxamer 188 (commercially named Pluronic F68 [PF68]) 
was purchased from BASF (Levallois Perret, France). All the 
solvents were provided at the highest grade by Carlo Erba 
(Milan, Italy). Water was purified using a Synergy (Millipore, 
Molsheim, France).
synthesis of rhodamine-tagged poly 
(lactide-co-glycolide)
A rhodamine B tertiary amide bearing a hydroxyl group30 
was linked to PLGA (Resomer RG503H) by a N,N′-
dicyclohexylcarbodiimide-assisted coupling reaction. 
The rhodamine B coupling reaction was performed as 
follows. In a round-bottomed flask, rhodamine B alcohol 
(105 mg, 0.17 × 10−3 mol) and PLGA (500 mg, 4.2 × 10−5 
mol) were dissolved in dichloromethane (50 mL). The 
resulting solution was bubbled for 30 minutes with N2 
while cooling to 0°C in an iced water bath. A solution 
of N,N′-dicyclohexylcarbodiimide (36 mg, 0.17 × 10−3 
mol) and a catalytic amount of 4-dimethylaminopyridine International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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in dichloromethane (10 mL) was added dropwise over   
20 minutes at 0°C under N2. The reaction mixture was 
allowed to warm to room temperature and then stirred for 
72 hours in the dark. The mother liquors were then concen-
trated, dissolved in a minimal amount of dichloromethane, 
and precipitated first in a large volume of cold diethyl ether 
and then in water. The precipitate of rhodamine B (Rhod)-
PLGA was filtered and dried under high vacuum, leading to 
425 mg of pure product as purple crystals (85% yield).
The coupling reaction yield was determined by 
  ultraviolet-visible spectroscopy. A precisely weighed amount 
of rhodamine B alcohol was dissolved in 10 mL of CHCl3. 
From this mother solution, dilutions were performed in the 
concentration range of 0.4 to 8 µM. The calibration curve 
was obtained by recording the absorbance of these different 
solutions at 563 nm. Finally, 10 mg of the Rhod-PLGA was 
dissolved into 5 mL of CHCl3, and the concentration of the 
solution was adjusted to an accurate precise value. The absor-
bance at 563 nm of this Rhod-PLGA solution was measured 
by ultraviolet-visible spectroscopy and the value was com-
pared with the theoretical one obtained from the calibration 
curve. The coupling yield was determined to be 25%.
Preparation of nanoparticles
Nanoparticles with different surface properties were pre-
pared by the solvent emulsion evaporation technique.31 
Neutral nanoparticles (PLGA/PVA nanoparticles) were 
prepared by dissolving 100 mg of PLGA (Resomer RG756) 
in 5 mL of a dichloromethane/acetone (1/1 v/v) mixture. This 
organic solution was pre-emulsified with 20 mL of a 0.25% 
(w/v) PVA (molecular weight 30–70 kDa) aqueous solution 
by vortexing for one minute. The pre-emulsion was kept on 
ice and sonicated for one minute using a VibraCell sonicator 
(Fisher Scientific, Illkirch, France) at 40% power. As for the 
positively-charged nanoparticles (PLGA/CS nanoparticles), 
the organic solution of PLGA was pre-emulsified with a 
0.6% (w/v) aqueous CS solution containing 0.5% (w/v) of 
Mowiol 4-88 PVA by vortexing for one minute. This pre-
emulsion was kept on ice and sonicated for 2 minutes using a 
VibraCell sonicator at 40% power. Then, for both the neutral 
and positively charged nanoparticles, the organic phase was 
allowed to evaporate at room temperature with magnetic 
stirring (600 rpm). Nanoparticle dispersion was then com-
pleted to 20 mL. The excess of stabilizers was removed by 
centrifugation of nanoparticles at 37,000 × g for one hour 
at 4°C, and the pellet of nanoparticles was resuspended in 
ultrapure water. Negatively charged nanoparticles (PLGA/
PF68 nanoparticles) were prepared using PF68 as   stabilizer. 
PLGA was dissolved in 10 mL of ethyl acetate and added 
drop wise into 20 mL of a 1% (w/v) aqueous solution of 
PF68 under vigorous magnetic stirring. The pre-emulsion 
was vortexed for one minute and then sonicated for another 
minute using a VibraCell sonicator at 40% power. Water 
(20 mL) was added to the emulsion, in order to promote 
diffusion of the organic solvent into the external phase, 
leading to formation of the nanoparticles. The organic phase 
was allowed to evaporate at room temperature with magnetic 
stirring (600 rpm). Rhodamine-tagged nanoparticles were 
prepared as described earlier by dissolving a 70/30% (w/w) 
mixture of PLGA (Resomer RG756) and Rhod-PLGA, in 
the organic solvent.
Nanoparticle size and zeta potential 
measurements
Nanoparticle average diameter was measured by dynamic light 
scattering with a Nano ZS (Malvern Instruments, Worcester-
shire, UK) with a 173° scattering angle at a temperature of 
25°C. Measurements were performed in triplicate following 
dilution of the nanoparticle dispersion in water. The surface 
charge of the nanoparticles was investigated by zeta potential 
measurement at 25°C, after dilution with NaCl 1 mM, using 
the Smoluchowski equation. The stability of the nanoparticles 
was investigated in water Ca2+ and Mg2+ free phosphate buf-
fer (PBS, Lonza, Levallois-Perret, France) and cell culture 
medium (DMEM, Lonza) containing 10% (v/v) of fetal bovine 
serum (Lonza). Particle size distribution was measured at 0, 
4, 24, 48, 72, and 96 hours after incubation at 37°C. Zeta 
potential in cell culture medium was measured according 
to the manufacturer’s instructions for measurement in high 
ionic strength media. Stability of the fluorescent labeling of 
nanoparticles was investigated by incubating Rhod-PLGA 
nanoparticles at 1 mg/mL in phosphate buffer at 37°C. At 
predetermined time intervals (8, 24, and 48 hours), an aliquot 
of the phosphate buffer medium was withdrawn and ultrafil-
tered (Nanosep Centrifugal Devices 3 kDa, Pall Corporation, 
Port Washington, NY) at 14,000 × g over 60 minutes, after 
which the soluble degradation products were collected in the 
bottom chamber. The absorbance of the filtered solution was 
measured by ultraviolet-visible spectroscopy, and the results 
were expressed as a percentage of the initial rhodamine con-
centration in the nanoparticle formulations.
Quantification of stabilizers associated  
to nanoparticles
The amount of PVA and chitosan associated to the nanopar-
ticles was indirectly measured by determining the concentration International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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in the supernatant after centrifugation of the nanoparticles. The 
amount of PVA was determined by a spectroscopic method 
based on the formation of a green-colored complex between two 
adjacent hydroxyl groups of PVA and iodine in the presence 
of boric acid.32 After centrifugation of the PLGA/PVA nano-
particles, appropriate volumes of the supernatant were diluted 
with water to 5 mL. A further 3 mL of boric acid solution (3.8% 
w/v) and 0.6 mL of a 0.1 M iodine solution were added and the 
volume was completed to 10 mL with water. The absorbance 
of the final solution was measured at 640 nm using boric acid 
and aqueous iodine solution as a blank. A calibration curve 
was prepared using PVA concentrations in the 5–50 µg/mL 
range. Absorbance was not influenced by the molecular weight 
of PVA. The presence of chitosan affected the colorimetric 
reaction. Therefore, to avoid any interference, chitosan was 
precipitated at pH 10 using 1 M NaOH. Samples were centri-
fuged at 12,100 × g for 5 minutes, and the supernatants were 
then analyzed to determine the PVA content. The   formation 
The amount of PF68 adsorbed onto the nanoparticles was 
determined according to equation 1:
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/
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× × 1000
 
  (1)
in which Ilact is the peak integral of the −CH groups of the lactide 
unit (δ = 5.2 ppm) corresponding to one proton; Iglyc is the peak 
integral of the −CH groups of the glycolide unit (δ = 4.8 ppm) 
corresponding to two protons; and IPF68 is the peak integral 
of the −CH and CH2 groups of the PF68 (δ = 3.4 – 3.7 ppm) 
corresponding to 695 protons. Mlact, Mglyc, and MPF68 are the 
molecular weights of the lactide unit (72 g/mol), the glycolide 
unit (58 g/mol), and the PF68 (8350 g/mol) unit, respectively; 
0.75 and 0.25 represent the percentage weight of the lactide 
and glycolide units in the PLGA used.
For the Rhod-PLGA nanoparticles, equation 1 was modi-
fied as follows:
of an ionic complex between the protonated chitosan amino 
groups and the sulfonic acid groups of Cibacron Brilliant Red® 
was used to measure the concentration of chitosan in the super-
natant after centrifugation of the PLGA/CS nanoparticles.33 In 
this assay, 0.1 M glycine buffer was prepared by dissolving 
glycine (1.87 g) and sodium chloride (1.46 g) in water and 
adding HCl to obtain a final pH value of 3.2. The dye solution 
was prepared by diluting an aqueous dye solution (0.15% w/v) 
with glycine buffer up to a final concentration of 0.075 mg/
mL. Thereafter, 20 µL of each sample was diluted to 300 µL 
with glycine buffer, and 3 mL of dye solution was then added. 
The absorbance values were measured at 576 nm, using the 
buffer and dye solution as a blank. The calibration curve was 
prepared in the 0–38 µg/mL range. The presence of PVA in 
the supernatant did not affect the reaction.
The amount of Pluronic adsorbed onto the PLGA/PF68 
nanoparticles was determined by  1H NMR following the 
protocol described by Trimaille et al,34 with some modifica-
tions according to the different polymer used. PLGA/PF68 
nanoparticles were centrifuged at 37,000 × g for one hour at 
4°C and the pellet was freeze-dried. The powder was then dis-
solved into deuterated chloroform, and 1H NMR analysis was 
carried out using a 300 mHz Bruker Avance (Lyon, France). 
(2)
In this equation, the use of PLGAs with different lactide/
glycolide ratios (PLGA 75/25 and Rhod-PLGA 50/50) and 
the molar percentage of the two polymers (0.363 and 0.637, 
respectively) has been considered.
Transmission electron microscopy
Transmission electron microscopy was performed using a 
Philips EM208 (Philips, Eindhoven, The Netherlands) oper-
ating at 60 kV . The suspension of nanoparticles (1 mg/mL) 
was deposited onto copper grids covered with a formvar film 
(400 mesh) for 2 minutes. Negative staining (30 seconds) 
with phosphotungstic acid 1% or uranyl acetate 0.5% was 
performed to observe the PLGA/PVA and PLGA/PF68 
nanoparticles or the PLGA/CS nanoparticles, respectively. 
The excess solution was blotted off using filter paper, and 
the grids were air dried before observation. Image acquisition 
was performed using a high-resolution camera, Advantage 
HR3/12GO4 (AMT-Hamamatsu).
surface analysis of particles
X-ray photoelectron spectroscopy was used to determine 
the surface composition of the nanoparticles. A Thermo 
Electron Escalab 250 spectrometer with monochromated 
N
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MI MI
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AlKα radiation (1486.6 eV) was used. The analyzer pass 
energy was 100 eV for survey spectra and 20 eV for high 
resolution spectra. The spectrometer was calibrated against 
Au 4f7/2 at 84.1 eV . O1 s and C1 s core levels were analyzed 
(Table S1). The photoelectron take-off angle (angle of the 
surface with the direction in which the photoelectrons are 
analyzed) was 90°. Curve fitting of the spectra was performed 
using Thermo Electron software. For calculation of the sur-
face composition, the inelastic mean free paths calculated by 
Tanuma et al35 and photoemission cross-sections calculated 
by Scofield were used.36
calu-3 cell line culture
The Calu-3 cell line was obtained from the American Tissue 
Type Collection (catalog number HTB-55) and maintained 
at 37°C and 5% CO2 in a humidified atmosphere. Cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, 
Lonza) supplemented with 50 U/mL penicillin, 50 U/mL 
streptomycin, and 10% fetal bovine serum (Lonza). The 
medium was changed every four days and cells were passed 
weekly at a 1/3 split ratio using Trypsine-EDTA (Lonza).
cell viability assay
The in vitro cytotoxicity of the nanoparticles was evaluated 
using the 3-[4,5-dimethylthiazol-2-yl]-3,5 diphenyl tetrazo-
lium bromide (MTT) test. This assay depends on the cellular 
reductive capacity to metabolize the MTT to a highly colored 
formazan product. Cells were seeded in 200 µL of growth 
medium (1.25 × 105 cells/mL) in 96-well plates (TPP, Zurich, 
Switzerland) and preincubated for 24 hours to recover. Then, 
100 µL of freshly prepared nanoparticle dispersions in fetal 
bovine serum-containing cell culture medium were added 
immediately after dilution to an appropriate concentration 
(0.03–5 mg/mL). The nanoparticle formulations were assayed 
for toxicity over 4, 24, and 72 hours of incubation. After 
the incubation period, 20 µL of a 5 mg/mL MTT solution 
in phosphate-buffered saline was added to each well. After 
2 hours, the culture medium was gently aspirated and replaced 
by 200 µL of dimethyl sulfoxide (American Chemical Soci-
ety grade, BioBasic Inc, Paris, France) in order to dissolve 
the formazan crystals. The absorbance of the solubilized 
dye, which correlates with the number of living cells, was 
measured with a microplate reader (LAB Systems Original 
Multiscan MS, Helsinki, Finland) at 570 nm. The percentage 
of viable cells in each well was calculated as the absorbance 
ratio between nanoparticle-treated and untreated control cells. 
Acrolein was used as the positive control at concentrations 
varying from 10−3 to 1 mM. The viability assay was used to 
assess the cytotoxicity of the different stabilizers used for the 
preparation of the nanoparticles. Stabilizer solutions in cell 
culture medium were appropriately diluted to a concentra-
tion corresponding to the amount present in the nanoparticle 
dispersion at a 1–5 mg/mL concentration range and incubated 
on the cells. The test was performed as described above.
confocal laser scanning microscopy
Confluent cells grown on six-well dishes were incubated for 
24 hours with Rhod-PLGA nanoparticles at 200 µg/mL. The 
monolayers were then washed with phosphate buffer. In vitro 
imaging acquisition was performed on living cells using a 
confocal laser scanning microscope LSM 510 META (Zeiss, 
Oberkochen, Germany) equipped with a 1 mW helium neon 
laser and a Plan-Apochromat 63× objective lens (numerical 
aperture 1.40, oil immersion). Red fluorescence was collected 
with a long-pass 560 nm emission filter under a 543 nm exci-
tation wavelength. The pinhole diameter was set at 104 µm. 
Stacks of images were collected every 0.8 µm along the 
z axis. Prior to observations, it was checked that the autofluo-
rescence of Calu-3 cells was negligible under the acquisition 
settings and did not interfere with the fluorescence coming 
from the nanoparticles.
Nanoparticle uptake kinetics in calu-3
For the uptake studies, confluent cells were incubated with 
Rhod-PLGA nanoparticles at 200 µg/mL. At different time 
points (4, 12, and 24 hours) monolayers were washed and the 
cells were incubated with Trypsine-EDTA for 10 minutes. Cell 
dispersion was centrifuged at 100 × g for 10 minutes and the 
pellet was recovered in an appropriate volume of phosphate 
buffer. The amount of Rhod-PLGA nanoparticles taken up 
by the Calu-3 cells was measured using a FACSCalibur® 
cell analyzer (Becton Dickinson, Franklin Lakes, NJ). The 
fluorescence emission was collected in the fluorescence-2 
channel. Cellular debris were eliminated from the analysis 
using a gate on forward and side scatter. For each sample, 
104 cells were analyzed. Experiments were performed in 
triplicate. Data acquisition and analysis were performed using 
the software CellQuest Pro version 4.02 (BD Biosciences, 
San Diego, CA).
cytokine secretion from calu-3 exposed 
to nanoparticles
Calu-3 cells were seeded in six-well dishes at a density 
of 106 cells per well in 1 mL culture medium and grown 
until confluence. Confluent cells were refreshed with 
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to nanoparticles at 200 µg/mL or lipopolysaccharide at   
10 µg/mL as a positive control. This concentration was found 
to be the minimal one ensuring a significant cytokine release 
after 24 hours of incubation. Unexposed cells were used as 
a negative control. Supernatants were collected at different 
intervals in time. Commercial enzyme-linked immunosorbent 
assay kits for interleukin-6 (IL-6), interleukin-8 (IL-8), and 
tumor necrosis factor alpha (TNFα) were used following 
the indications of the manufacturer (R&D Systems Europe 
Ltd, France).
statistical analysis
The differences between cells exposed to nanoparticles or 
the positive control and untreated cells were evaluated using 
a Student’s t-test. Statistical significance was indicated as 
P , 0.05 or P , 0.01. The symbols used are reported in the 
legend for each figure.
Results
Design and characterization of PLGA 
nanoparticles
The nanoparticles were prepared according to an emulsion 
evaporation technique, as described in the Materials and 
methods section. As shown in Table 1, introduction of dif-
ferent stabilizers allowed modification of the nanoparticle 
surface charge. One cationic stabilizer, ie, CS, was used as 
well as two neutral stabilizers, ie, partially hydrolyzed PVA 
and PF68. PLGA/PF68 nanoparticles had a mean diameter 
of 100 nm, while both PLGA/PVA and PLGA/CS nanopar-
ticles were around 200 nm (Table 1). All formulations had 
a narrow size distribution, with a polydispersity index of 
0.1–0.2 (Table 1). These results are in agreement with the 
transmission electron microscopic images (Figure 1) that 
show spherical nanoparticles with a smooth surface. Zeta 
potential measurements confirmed that the stabilizers influ-
ence nanoparticle surface charge. PLGA/CS nanoparticles 
exhibited a positive zeta potential (+32 ± 3 mV), whereas 
PLGA/PVA nanoparticles were almost neutral (−5 ± 1 mV), 
and PLGA/PF68 nanoparticles exhibited a negative zeta 
potential (−24 ± 1 mV), as shown in Table 1.
The presence of stabilizers on the nanoparticle surface 
was confirmed by x-ray photoelectron spectroscopy, where 
the spectra associated with each nanoparticle differed from 
the pure PLGA spectrum. Indeed, the fits of the C1 s and 
O1 s envelopes of PLGA nanoparticles showed peaks which 
were due to the simultaneous presence of both PLGA and 
stabilizer (supporting information, Table S1). The amount 
of stabilizers associated with the nanoparticle surface were 
quantified by spectrophotometric methods or 1H NMR spec-
troscopy. Between 10 mg and 30 mg of stabilizer (per 100 mg 
of PLGA) was found to be associated with the nanoparticles 
(Table 1).
A hydroxyl derivative of rhodamine B (Rhod-OH) was 
covalently linked to PLGA, and the resulting tagged polymer 
(Rhod-PLGA) was used for the preparation of fluorescent 
nanoparticles by simply blending it with unmodified PLGA. 
Use of Rhod-PLGA did not influence either the size distri-
bution or the surface charge of the nanoparticles. The only 
exception was the Rhod-PLGA/CS nanoparticles, the size 
and zeta potential of which decreased slightly (Table 1). 
Therefore, x-ray photoelectron spectroscopy was used to 
investigate the presence of rhodamine on the nanoparticle 
surface. The O1 s peak-fitted envelopes for the PLGA/CS 
nanoparticles and Rhod-PLGA/CS nanoparticles is reported 
in Figure S1. The two main components of the O1 s peak of 
the PLGA/CS nanoparticles are centered at binding energies 
of 533.1 eV and 534.7 eV , and assigned to Oa nd O C-OH C-O-C, 
respectively, while for the Rhod-PLGA/CS nanoparticles, the 
O1 s envelope shows three major peaks which correspond to 
OC=O (532.4 eV), OC-OH  (534.1 eV), and OC-O-C  (535.8 eV) 
environments. The presence of a third signal, the binding 
energy of which can be assigned to carbonyl groups, confirms 
the presence of rhodamine moieties on the surface of the 
Rhod-PLGA/CS nanoparticles. However, x-ray photoelectron 
spectroscopy analysis of the PLGA/PVA nanoparticles and 
PLGA/PF68 nanoparticles did not reveal any modification 
due to the presence of rhodamine (Table S1).
The stability of the linkage between rhodamine and 
nanoparticles was investigated over 48 hours in Dulbecco’s 
phosphate-buffered saline at 37°C. The results confirm that 
the covalent bond between the dye and the PLGA was highly 
Table 1 Physicochemical properties of unlabeled and rhodamine-
labeled nanoparticles
Nanoparticle  
type
Mean  
diameter  
(nm)
PDI Zeta  
potential  
(mV)
Associated  
stabilizers  
(mg/100 mg  
PLGA)
PLgA/cs 230 ± 6 0.20 +32 ± 3 15.3 ± 3.3 (cs)  
30.4 ±1.8 (PVA)
PLgA/PVA 230 ± 2 0.12 −5 ± 1 11.5 ± 1.1 (PVA)
PLgA/PF68 105 ± 2 0.13 −24 ± 1 10.7 ± 3.7 (PF68)
rhod-PLgA/cs 174 ± 3 0.20 +13 ± 1 20.5 ± 4.8 (cs)  
31.8 ± 2.6 (PVA)
rhod-PLgA/PVA 226 ± 4 0.09 −5 ± 1 12.4 ± 1.0 (PVA)
rhod-PLgA/PF68 100 ± 2 0.13 −20 ± 2 10.6 ± 2.1 (PF68)
Abbreviations: PLgA, poly (lactide-co-glycolide); PVA, poly (vinyl alcohol); cs, 
chitosan; rhod, rhodamine B; PF68, Pluronic® F68; PDI, polydispersity index.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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stable, because only a small amount of free rhodamine was 
recovered. After 24 hours, a maximum of 7.5% of the dye 
leaked out from the nanoparticles without any significant fur-
ther release during the following 24 hours of incubation.
To monitor for any possible size and zeta potential variation 
upon exposure to the different experimental environments, the 
nanoparticles were incubated for 96 hours at 37°C in three 
different media, ie, water, cell culture medium (DMEM) 
containing 10% fetal bovine serum, and phosphate buffer. In 
each medium, the size distribution was followed as a function 
of incubation time (Table 2). Interestingly, regardless of their 
surface charge, the size of the nanoparticles was not signifi-
cantly different in water and in cell culture medium containing 
fetal bovine serum. A size increase was observed only for 
PLGA/CS nanoparticles after incubation in phosphate buffer. 
Moreover, the zeta potential values for the nanoparticles did not 
show significant modification in cell culture medium contain-
ing fetal bovine serum either (+8 ± 3, −2 ± 1, and −18 ± 3 mV 
for PLGA/CS, PLGA/PVA, and PLGA/PF68, respectively). 
On the basis of these results, cell culture medium containing 
fetal bovine serum was selected for dilution of nanoparticles 
to appropriate concentrations for the in vitro studies.
effect of nanoparticle concentration  
and surface chemistry on cell viability, 
uptake, and inflammatory response
Calu-3 cell viability was investigated as a function of 
nanoparticle concentration (0.03–5 mg/mL) using the MTT 
assay. This quantitative colorimetric test is based on the ability 
of viable cells to metabolize the water-soluble dye (MTT) into 
a colored formazan salt. After 72 hours of incubation, cell 
viability was always higher than 50%, even at the highest con-
centration tested (Figure 2). Cell viability initially diminished 
as the nanoparticle concentration increased up to 0.3 mg/mL, 
and then reached a plateau. Only after exposure to the PLGA/
PF68 nanoparticles did cell viability progressively decrease 
and drop to 57% ± 2% at 5 mg/mL. Furthermore, the contri-
bution of stabilizers to cytotoxicity was assessed, revealing 
that cell viability was higher in the presence of the stabilizer 
solutions than after incubation with nanoparticle suspensions 
containing the same amount of stabilizers (Figure 3).
Neither the nanoparticle formulations nor the different 
stabilizers, when assayed separately, led to a reduction in cell 
viability below 50%. A wide range of concentrations was 
tested to screen the toxicity of the nanoparticles   accurately 
AB C
100 nm 100 nm 100 nm
Figure 1 Transmission electron microscopic images of (A) PLgA/cs nanoparticles, (B) PLgA/PVA nanoparticles, and (C) PLgA/PF68 nanoparticles.
Abbreviations: PLgA, poly (lactide-co-glycolide); PVA, poly (vinyl alcohol); PF68, Pluronic® F68; cs chitosan.
Table 2 evolution of mean diameter of PLgA/cs, PLgA/PVA, 
and PLgA/PF68 nanoparticles at 37°C as a function of time (size 
is expressed in nm unless otherwise stated). Nanoparticles were 
incubated and measured in water, cell culture medium containing 
10% fetal bovine serum, and ca²+ and Mg²+ free phosphate buffer
Experimental  
medium
Time  
(h)
Nanoparticle type
PLGA/ 
CS
PLGA/ 
PVA
PLGA/ 
PF68
0 230 ± 8 210 ± 6 103 ± 2
4 218 ± 6 205 ± 5 102 ± 5
h20 24 227 ± 7 203 ± 5 101 ± 2
48 212 ± 3 201 ± 6   98 ± 4
72 225 ± 8 201 ± 4 103 ± 2
96 215 ± 3 204 ± 3 102 ± 3
4 217 ± 36 159 ± 12 113 ± 4
24 166 ± 13 141 ± 6 123 ± 8
DMeM + 10% FBs 48 173 ± 10 157 ± 5 131 ± 9
72 216 ± 26 156 ± 5 128 ± 5
96 188 ± 12 156 ± 6 134 ± 9
4 688 ± 86 198 ± 9 114 ± 4
24 851 ± 113 197 ± 5 102 ± 3
PBs 48 .1 µm 200 ± 4 115 ± 5
72 .1 µm 202 ± 4 112 ± 2
96 .1 µm 201 ± 3 111 ± 3
Note: Data represent the mean ± standard deviation (n = 3). 
Abbreviations: FBs, fetal bovine serum; PLgA, poly (lactide-co-glycolide); PVA, 
poly (vinyl alcohol); PF68, Pluronic® F68; cs, chitosan; PBs, phosphate-buffered 
solution; DMEM, Dulbecco’s modified Eagle’s medium.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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over an incubation time that allowed cells to remain in 
exponential growth and undergo doubling. To confirm the 
absence of any acute toxicity, cell viability was investigated 
after 4 and 24 hours of incubation (Figure 4). Exposure of 
Calu-3 cells to PLGA/PVA and PLGA/CS nanoparticles 
for 4 hours did not affect their viability as compared with 
untreated cells. At 4 hours, following exposure to PLGA/
PF68 nanoparticles, an increase in cell viability was found. 
No significant differences were observed as a function 
of nanoparticle concentration. A mild adverse effect was 
evident after 24 hours, especially with PLGA/PVA nano-
particles, which caused a decrease in cell viability down to 
80% at a concentration of 5 mg/mL. In subsequent studies, 
0.2 mg/mL was used to ensure at least 80% cell viability. 
By contrast, incubation of acrolein, used as control with the 
same Calu-3 cells, caused a 50% reduction in viability at a 
concentration of 17 µg/mL (data not shown).
The influence of surface chemistry and surface charge on 
the ability of Calu-3 cells to internalize nanoparticles was 
then investigated. After 24 hours of incubation with rhod-
amine-tagged nanoparticles, the cells were washed with fresh 
medium to remove the membrane-bound nanoparticles. The 
cellular uptake of nanoparticles was then observed in living 
cells by confocal laser scanning microscopy. No morphologi-
cal alteration of the cells was detected on Nomarski images, 
confirming the results obtained by MTT.   Fluorescence images 
and their superimposition on Nomarski images show that 
fluorescent spots accumulate within the cells and   especially 
around the nuclei, demonstrating the interaction of the 
nanoparticles with cells and their intracellular accumula-
tion, most probably into intracellular vacuoles (Figure 5). 
In addition, no difference could be observed between the 
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Figure 2 calu-3 cell viability (MTT assay) after 72 hours of exposure to PLgA/cs, 
PLgA/PVA, and PLgA/PF68 nanoparticles (0.030–5 mg/mL). each experiment was 
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Figure 3 calu-3 cell viability (MTT assay) after 72 hours of exposure to (A) PLgA/
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different nanoparticles (Figures S2 and S3). These results 
were confirmed also by flow cytometry measurement of cell-
associated levels of Rhod-PLGA nanoparticles. Despite their 
different surface properties, the internalization profiles of the 
PLGA nanoparticles were similar (Table S2).
To assess whether biodegradable nanoparticles induced an 
inflammatory phenotype in the Calu-3 cell line as a function 
of their surface properties, we investigated their effect on 
different markers of inflammation, ie, TNFα, IL-6, and IL-8. 
The release of cytokines was investigated over 48 hours of 
exposure to nanoparticles (0.2 mg/mL) using lipopolysaccha-
ride as a positive control (10 µg/mL, Figure 6A and B). The 
concentration of lipopolysaccharide chosen was consistent 
with previous work.37,38
As expected, a basal concentration of cytokines in the 
supernatant was detected in control cells.39 Remarkably, no 
effect of treatment with nanoparticles, regardless of their 
physicochemical surface properties, was observed, with IL-8 
and IL-6 concentrations in the supernatant not being different 
between the treatment groups. IL-8 was secreted at a higher 
concentration compared with IL-6, and a significant increase 
in IL-8 release over time was found only for the positive 
control (P , 0.05 and P , 0.01 for cells exposed to lipopoly-
saccharide compared with control or nanoparticle-exposed 
cells at 24 hours and 48 hours, respectively). TNFα was not 
detected in any of the samples, thus indicating an absence of 
response after incubation with nanoparticles.
Discussion
Nanoparticles were modified by three different stabilizing 
agents, ie, CS, PVA, or PF68, in order to study the   influence 
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Figure 4 evolution of calu-3 cell viability (MTT assay) after exposure to (A) PLgA/
cs, (B) PLgA/PVA, and (C) PLgA/PF68 nanoparticles as a function of time. each 
experiment was repeated eight times from three independent incubation preparations. 
results are expressed as percentages of absorption for treated cells (± standard 
deviation) in comparison with untreated control cells. 
Notes: The significance was indicated as *P , 0.05 (24 hours versus 4 hours) and 
#P , 0.05 (72 hours versus 24 hours).
Abbreviations: PLgA, poly (lactide-co-glycolide); PVA, poly (vinyl alcohol); PF68, 
Pluronic® F68; cs, chitosan; NPs, nanoparticles.
Figure 5 real time confocal laser scanner microscopy images of calu-3 cells exposed 
to  rhod-PLgA/PVA  nanoparticles  for  24  hours  and  subsequent  washing  of  the 
medium. (A) Nomarski image, (B) fluorescent image, and (C) superimposition of 
Nomarski and fluorescence images, and (D) enlarged region of (C). 
Note: scale bars = 20 µm.
Abbreviations: PLgA, poly (lactide-co-glycolide); PVA, poly (vinyl alcohol); rhod, 
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of surface properties on their toxicity. It was observed 
that nanoparticles made of PLGA/CS displayed a positive 
charge that could have arisen from electrostatic interactions 
between the negatively charged groups of PLGA and the 
positively charged CS that induce adsorption of CS onto the 
nanoparticle surface. Only a fraction of the amino groups 
were required to neutralize the negative charges of PLGA, 
whereas the remaining free amino groups were responsible 
for the resulting positive zeta potential. Similarly, the surface 
properties of PLGA/PVA nanoparticles were the result of the 
adsorption of PVA (which is a partially hydrolyzed poly(vinyl 
acetate), containing vinyl alcohol and vinyl acetate monomer 
units). The hydrophobic acetate moieties confer amphiphilic 
properties to PVA that may adsorb at the organic phase-water 
interface during particle formation, leading to its entrap-
ment within the PLGA matrix on the nanoparticle surface.40 
Given its high molecular weight (30–70 kDa), the PVA layer 
was able to screen PLGA charges, leading to an almost 
neutral zeta potential value. PF68, a polyoxyethylene-block–
polyoxypropylene-block-polyoxyethylene (PEO-b-PPO-
b-PEO) triblock polymer, is also neutral but with a lower 
molecular weight (8.4 kDa). Therefore, its adsorption on 
the nanoparticle surface may cause only a partial screening 
of PLGA charges,41 resulting in negatively charged nano-
particles. It was also important to verify that rhodamine 
used to label the nanoparticles for in vitro tracking did not 
change these surface properties significantly. Rhodamine was 
selected because its emission wavelengths are higher than 
those commonly associated with autofluorescence in cells.42 
Formulation of nanoparticles with a chemically modified 
polymer was chosen instead of using physically entrapped 
dyes due to possible desorption and release of the fluorescent 
molecule and consequent misinterpretation of the imaging 
results.43,44 The fluorescent dye did not affect the nanoparticle 
size; indeed, the slight size decrease from 230 nm to 170 nm 
observed for the Rhod-PLGA/CS nanoparticles was not due 
to the presence of rhodamine but to the use of a mixture of 
different molecular weight PLGAs. This was confirmed by 
a control formulation obtained with unlabelled PLGAs. 
Electrostatic interactions between CS (the only charged 
stabilizer used in this study) and the fluorescent probe led 
to a surface distribution of positively charged rhodamine 
moieties that might explain the decreased zeta potential. 
Indeed, the zeta potential represents the overall charge of the 
slipping plane, ie, the cloud of ions surrounding the surface 
of the particles, which is influenced by the composition of 
the nanoparticle surface.45 The stabilizers did not carry any 
charge in these formulations, confirming that the presence 
of rhodamine on the Rhod-PLGA/CS nanoparticle surface 
arises from electrostatic interactions with CS. Importantly, 
the covalent bond between the dye and the PLGA was shown 
to be highly stable, with only a small amount of rhodamine 
being detected in the release medium. These results, which 
are in good agreement with those obtained with rhodamine-
tagged poly (alkyl cyanoacrylate) nanoparticles,46 may also 
be correlated with the initial formation of small amounts of 
soluble fluorescent degradation products and their diffusion 
into the medium.47
The stability of the nanoparticles in biological medium 
was tested, and they were mostly stable after incubation in 
culture medium containing fetal bovine serum. Such good 
stability could be explained by the fact that nanoparticle 
aggregation was probably prevented by serum proteins which 
adsorb onto their surface, thus taking part in their   stabilization 
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via steric repulsion. A size increase was   obvious only for 
PLGA/CS nanoparticles after incubation in phosphate 
buffer, which may be due to the screening of electrostatic 
repulsion as a result of the ionic strength of the buffer. The 
results recorded for PLGA/PVA and PLGA/PF68 nanopar-
ticles confirm their stabilization by steric repulsion due to 
stabilizer adsorption at their surface, as long as they are not 
affected by the electrolyte concentration in the experimental 
medium.48
Within the airways, the epithelial cells are the first inter-
face encountered by inhaled materials. Although alveolar 
epithelial cells have often been used as in vitro models to 
investigate the lung toxicity of various nanoparticles, local 
bronchial deposition, due to the impact of the inhaled nano-
particles on the bifurcations of the airways, has to be consid-
ered due to their important role in the development of lung 
cancer.49 While the most important function of alveolar epi-
thelial cells is gas exchange, bronchial cells play a critical role 
in defense mechanisms against xenobiotics due to the produc-
tion of mucus and the presence of cilia which allow deposited 
material to be swept out of the lung. Furthermore, bronchial 
epithelial cells are able to express cytokines, chemokines, and 
adhesion molecules.50–52 To assess the in vitro toxicity of the 
nanoparticles, we chose the Calu-3 cell line previously used 
to assess the toxicological profiles of environmental matter 
and colloidal systems.6 The Calu-3 cell line derives from a 
human adenocarcinoma, and constitutes a well established in 
vitro model of lung epithelium.21 Calu-3 cells secrete mucus 
and have apically located cilia mimicking the physiological 
conditions of the upper airways.53
The results for the viability of Calu-3 after exposure to 
nanoparticles showed that viability starts to decrease only at 
very high concentrations, highlighting the safety of nano-
particles, independently of their chemical composition and 
surface properties. After short exposure (4 hours) to PLGA/
PF68 nanoparticles, an increase in cell viability was found. 
This result may be explained by a nonspecific response 
causing rapid and transient activation of cell metabolism, 
probably leading to an increase in the cellular capacity to 
reduce MTT. The absence of differences as a function of 
nanoparticle concentration and the high value of the standard 
deviations support the hypothesis of a nonspecific response 
to applied stress, which did not have a homogeneous effect. 
Moreover, the different behavior of the nanoparticles observed 
at 24 hours compared with 4 hours suggests a rapid response 
which takes place only during the first hours of exposure to 
the PLGA/PF68 nanoparticles. Only acrolein, which is the 
strongest irritant component among the various constituents 
of cigarette smoke, caused a 50% reduction in cell viability, 
confirming that PLGA nanoparticles lack toxicity. The PLGA 
nanoparticles only affected the viability of Calu-3 cells at 
concentrations that are too high for clinical use. The low 
cytotoxicity is confirmed by other studies of lung cells, such 
as the A549 cell line, where concentrations of 5 mg/mL were 
reached without cytotoxicity.54 The absence of inflammation 
using PLGA nanoparticles has been described previously.55
However, stimulation of epithelial cells by non-biodegradable 
nanoparticles exhibiting different physicochemical properties 
led to lung inflammation characterized by secretion of different 
mediators that can cause differentiation, chemotaxis, or activa-
tion of inflammatory cells.56,57 This is why we investigated the 
effect of surface-modified nanoparticles on the production of 
TNFα, an acute inflammatory response cytokine; IL-6, which 
is responsible for neutrophil activation; and IL-8 that exerts a 
chemotactic action on inflammatory cells. Lipopolysaccharide 
was used as a positive control. In contrast with lipopolysac-
charide, no significant increase in these inflammation markers 
was observed. These results are of great importance consider-
ing the role of these cytokines in the inflammatory response 
and their ability to activate almost any type of cell. Moreover, 
the absence of TNFα suggests a lack of biological effect on 
other cells of the airway epithelium. Altogether, these results 
show that biodegradable nanoparticles composed of PLGA 
did not cause any inflammatory activation in this in vitro 
model of lung epithelium and exclude the influence of differ-
ent physicochemical surface properties of the nanoparticles 
in the cellular inflammatory response.
Conclusion
This study is among the first attempts to investigate system-
atically the fundamental role of physicochemical surface 
properties on the potential in vitro lung toxicity of biodegrad-
able PLGA nanoparticles. Nanoparticles are internalized by 
Calu-3 cells and induce low toxicity even at high concentra-
tions, independently of their surface chemistry and charge. 
Furthermore, exposure to nanoparticles does not promote 
the release of TNFα, IL-6, and IL-8, confirming the absence 
of inflammatory activation potential. These in vitro results 
highlight the safety of biodegradable PLGA nanoparticles on 
the bronchial epithelium and provide the first data on their 
potential effects and the risks associated with their use as 
colloidal nanomedicines.
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Table S1 X-ray photoelectron spectroscopic analysis of the different C1s and O1s peak fitting intensities of the polymers before and 
after particle formulation
Sample XPS C1s envelope ratio (%) XPS O1s envelope ratio (%)
CC-C CC-O CC=O OC=O OO-C=O OC-OH O C-O-C
PLgA 24.8 35.0 40.2 62.4 37.6 – –
cs 14.0 69.0(2) 17.0 – – 39.7 60.3
PVA 47.9 45.1 7.0 36.4 – 63.6 –
PF68 100.0(1) – – – – 24.1 75.9
rhod-Oh 48.4 45.2 6.4 8.9 – 75 16.1
rhod-PLgA 49.9 43.4 6.7 10.1 – 71.8 18.1
PLgA/cs nanoparticles 25.6 54.0(2) 20.4 – – 76.1 23.9
PLgA/PVA nanoparticles 37.7 35.7 26.6 42.3 14.0 43.7 –
PLgA/PF68 nanoparticles 35.1 41.9 23.0 30.2 19.3 – 50.5
rhod-PLgA/cs nanoparticles 28.0 45.0(2) 27.0 41.2 – 42.3 16.5
rhod-PLgA/PVA nanoparticles 35.0 36.4 28.6 41.3 12.8 45.9 –
rhod-PLgA/PF68 nanoparticles 31.0 51.0 18.0 83.0(3) 17.0 – –
Notes:  (1)  Peak  corresponds  to  cc-O  and  cc-N  environments;  (2)  Peak  corresponds  to  cc-O  and  cc-N  environments;  (3)  Peak  corresponds  to  Oc=O  and  cc-O-c 
environments.
Abbreviations: rhod, rhodamine B; PLgA, polylactide-co-glycolide; PVA, polyvinyl alcohol; PF68, Pluronic® F68; cs, chitosan; XPs, x-ray photoelectron spectroscopy.
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Figure S1 Oxygen O1 s envelopes of x-ray photon spectroscopic analysis from 
(A) PLgA/cs nanoparticles and (B) rhod-PLgA/cs nanoparticles.
Abbreviations:  rhod,  rhodamine  B;  PLgA,  poly  (lactide-co-glycolide);  cs, 
chitosan.
Table S2 Fluorescence variation with calu-3 cells after exposure 
to  rhod-PLgA/cs,  rhod-PLgA/PVA,  and  rhod-PLgA/PF68 
nanoparticles. Red fluorescence was measured at 4, 12, and 24 
hours 
Percentage of cells above fluorescence 
threshold
4 hours 12 hours 24 hours
rhod-PLgA/cs 9.1 ± 1.1 13.4 ± 1.8 21.5 ± 4.4
rhod-PLgA/PVA 7.6 ± 2.3 14.4 ± 4.7 20.3 ± 3.8
rhod-PLgA/PF68 9.0 ± 1.0 15.8 ± 1.6 28.4 ± 4.3
Notes: The results were obtained after gating and selection of a fluorescence 
threshold. 10,000 cells were counted per sample. Data are expressed as the mean ± 
standard deviation (n = 3).
Abbreviations: rhod, rhodamine B; PLgA, poly (lactide-co-glycolide); PVA, poly 
(vinyl alcohol); PF68, Pluronic® F68; cs, chitosan.
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Figure S2 real time confocal laser scanner microscopy images of calu-3 cells exposed to rhod-PLgA/cs nanoparticles for 24 hours and subsequent washing of the medium. 
(A) Nomarski image, (B) fluorescent image, and (C) superimposition of Nomarski and fluorescence images. (D, E, and F) show enlarged pictures. 
Note: scale bars = 20 µm.
Abbreviations: rhod, rhodamine B; PLgA, poly (lactide-co-glycolide); cs, chitosan.
Figure S3 real time confocal laser scanner microscopy images of calu-3 cells exposed to rhod-PLgA/PF68 nanoparticles for 24 hours and subsequent washing of the 
medium. (A) Nomarski image, (B) fluorescent image, and (C) superimposition of Normaski and fluorescence images. (D, E, and F) show enlarged pictures. 
Note: scale bars = 20 µm.
Abbreviations: rhod, rhodamine B; PLgA, poly (lactide-co-glycolide); PF68, Pluronic® F68.